https://www.biopharmawatch.com/news/NAIA/naia-relief-alumni-perks-partnership-well-being-support BiopharmaWatch en 2026-09-28T11:00:00.000Z naia Relief Inc. Announces Strategic Partnership with Alumni-Perks to Expand Access to 24/7 Well-Being Support for Canadian University/College Alumni https://www.biopharmawatch.com/news/BRKR/bruker-advances-functional-proteomics-timsultra-timsomni BiopharmaWatch en 2026-09-28T11:00:00.000Z Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research https://www.biopharmawatch.com/news/ANTX/antx-funding-extension-tuberculosis-research-gsk BiopharmaWatch en 2026-09-28T11:00:00.000Z AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK https://www.biopharmawatch.com/news/CSTL/tissuecypher-study-management-non-dysplastic-barretts-esophagus BiopharmaWatch en 2026-09-28T11:00:00.000Z New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-banyan-trial-als-foralumab BiopharmaWatch en 2026-09-28T11:00:00.000Z Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-virtual-kol-event-denifanstat-update BiopharmaWatch en 2026-09-28T11:00:00.000Z Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026 https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-bh-501284-aacr-conference BiopharmaWatch en 2026-09-28T11:00:00.000Z BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer https://www.biopharmawatch.com/news/ARVN/arvinas-phase-1-2-trial-arv-6723 BiopharmaWatch en 2026-09-28T11:00:00.000Z Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-launches-impavido-capsules BiopharmaWatch en 2026-09-28T10:50:00.000Z Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules https://www.biopharmawatch.com/news/PFE/pfizer-advances-cancer-care-esmo-2026 BiopharmaWatch en 2026-09-28T10:45:00.000Z Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO https://www.biopharmawatch.com/news/MRK/merck-exclusive-license-agreement-sci-brunch-spr2015 BiopharmaWatch en 2026-09-28T10:45:00.000Z Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor https://www.biopharmawatch.com/news/ACET/adicet-bio-prula-cel-safety-efficacy-data-sle BiopharmaWatch en 2026-09-28T10:45:00.000Z Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis https://www.biopharmawatch.com/news/WELL/well-health-wellstar-tsxv-listing-approval BiopharmaWatch en 2026-09-28T10:00:00.000Z WELL Health Subsidiary WELLSTAR Announces Conditional Approval for TSXV Listing and Files Filing Statement https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-dr-michael-white-promotion BiopharmaWatch en 2026-09-28T10:00:00.000Z IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development https://www.biopharmawatch.com/news/ZYME/zymeworks-theravance-biopharma-acquisition-financial-guidance BiopharmaWatch en 2026-09-28T10:00:00.000Z Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition https://www.biopharmawatch.com/news/MNOV/medicinova-topline-results-mn-001-natg-202-trial BiopharmaWatch en 2026-09-28T10:00:00.000Z MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) https://www.biopharmawatch.com/news/YI/111-inc-establishes-special-committee BiopharmaWatch en 2026-09-28T08:30:00.000Z 111, Inc. Announces Establishment of the Special Committee https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-09-28 BiopharmaWatch en 2026-09-28T07:15:32.098Z IGALMI PDUFA for Agitation in Bipolar Disorder: Biotech Catalysts Sep 28, 2026 https://www.biopharmawatch.com/news/STAA/staars-consumer-survey-vision-correction-germany BiopharmaWatch en 2026-09-28T07:00:00.000Z Verbraucherumfrage von STAAR Surgical: 71 Prozent der Deutschen möchten auf Sehhilfen verzichten, kennen aber ihre Alternativen nicht https://www.biopharmawatch.com/news/TMO/thermo-fisher-evosep-reseller-agreement BiopharmaWatch en 2026-09-28T07:00:00.000Z Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno https://www.biopharmawatch.com/news/MEDS/datameds-ai-tollo-health-launch-health-lives-here-app BiopharmaWatch en 2026-09-28T06:00:00.000Z DataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile Application https://www.biopharmawatch.com/news/DXCM/dexcom-report-easd-2026-diabetes-care-opportunity BiopharmaWatch en 2026-09-28T06:00:00.000Z Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care https://www.biopharmawatch.com/news/IVA/inventiva-reports-2026-first-half-financial-results BiopharmaWatch en 2026-09-28T06:00:00.000Z Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/QGEN/qiagen-fda-clearance-qiastat-dx-bacteria-panel BiopharmaWatch en 2026-09-28T05:30:00.000Z QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-2026-half-year-results-update BiopharmaWatch en 2026-09-28T05:00:00.000Z Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-investor-call-azure-1-study BiopharmaWatch en 2026-09-27T21:00:00.000Z Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 https://www.biopharmawatch.com/news/ARAY/accuray-samsung-neurologica-collaboration-cyberknife BiopharmaWatch en 2026-09-27T15:15:00.000Z Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform https://www.biopharmawatch.com/news/ASTS/ast-spacemobile-securities-fraud-class-action BiopharmaWatch en 2026-09-26T15:33:00.000Z AST SpaceMobile, Inc. (NASDAQ: ASTS) Investors: November 13, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP